Last reviewed · How we verify
Levoamlodipine Maleate Table — Competitive Intelligence Brief
phase 2
Calcium channel blocker
L-type calcium channels
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Levoamlodipine Maleate Table (Levoamlodipine Maleate Table) — Hasten Biopharmaceutical Co., Ltd.. Calcium channel blocker
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Levoamlodipine Maleate Table TARGET | Levoamlodipine Maleate Table | Hasten Biopharmaceutical Co., Ltd. | phase 2 | Calcium channel blocker | L-type calcium channels | |
| Perindopril + amlodipine + if necessary, hydrochlorothiazide | Perindopril + amlodipine + if necessary, hydrochlorothiazide | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | marketed | ACE inhibitor + calcium channel blocker + thiazide diuretic combination | Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter | |
| DHP | DHP | Centro de Investigacao em Saude de Manhica | marketed | calcium channel blocker | L-type calcium channels | |
| losartan/amlodpine | losartan/amlodpine | University of Pavia | marketed | Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB) | Angiotensin II receptors (AT1) and L-type calcium channels | |
| Verapamil Hydrochloride | Verapamil Hydrochloride | Pfizer Inc. | marketed | Calcium channel blocker | L-type calcium channels (slow channels) | |
| Phase B: Triplixam / Elestar HCT | Phase B: Triplixam / Elestar HCT | National Institute of Cardiology, Warsaw, Poland | marketed | Fixed-dose combination antihypertensive (calcium channel blocker + ARB + thiazide diuretic) | L-type calcium channels, angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter | |
| Lotrel (amlodipine/benazepril) | Lotrel (amlodipine/benazepril) | Abbott | marketed | Calcium channel blocker / ACE inhibitor combination | L-type calcium channels (amlodipine); Angiotensin-converting enzyme (benazepril) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Calcium channel blocker class)
- Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
- Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
- Ain Shams University · 1 drug in this class
- Bioprojet · 1 drug in this class
- Bristol-Myers Squibb · 1 drug in this class
- GlaxoSmithKline · 1 drug in this class
- Handok Inc. · 1 drug in this class
- Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
- Hospital de Clinicas de Porto Alegre · 1 drug in this class
- Laboratorios Richmond S.A.C.I.F. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Levoamlodipine Maleate Table CI watch — RSS
- Levoamlodipine Maleate Table CI watch — Atom
- Levoamlodipine Maleate Table CI watch — JSON
- Levoamlodipine Maleate Table alone — RSS
- Whole Calcium channel blocker class — RSS
Cite this brief
Drug Landscape (2026). Levoamlodipine Maleate Table — Competitive Intelligence Brief. https://druglandscape.com/ci/levoamlodipine-maleate-table. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab